In a report released on November 23, Joel Beatty from Robert W. Baird maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price target of $112.00. The company’s shares closed last Friday at $96.92.
Beatty covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Cardiff Oncology, and Editas Medicine. According to TipRanks, Beatty has an average return of -0.9% and a 44.72% success rate on recommended stocks.
In addition to Robert W. Baird, BioMarin Pharmaceutical also received a Buy from SVB Securities’s Joseph Schwartz in a report issued on November 23. However, on the same day, Wedbush reiterated a Hold rating on BioMarin Pharmaceutical (NASDAQ: BMRN).
See the top stocks recommended by analysts >>
The company has a one-year high of $99.74 and a one-year low of $70.73. Currently, BioMarin Pharmaceutical has an average volume of 1.29M.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.
Read More on BMRN:
- BioMarin Voxzogo concerns lowered by Ascendis data, says Morgan Stanley
- BioMarin should rally ‘meaningfully’ after Ascendis data, says Piper Sandler
- ‘History points to a post-midterm rally:’ Oppenheimer suggests 3 stocks to ride the momentum
- American Association for Study of Liver Diseases to hold a meeting
- BioMarin provides update on BLA for valoctocogene roxaparvovec AAV gene therapy
